期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP450氧化还原酶遗传多态性对CYP酶影响的研究进展 被引量：3

Progress on influence of cytochrome P450oxidoreductase polymorphisms on cytochrome P450monoxyfenases
下载PDF
导出
摘要 细胞色素P450氧化还原酶(CytochromeP450oxidoreductase,POR)是将电子从NADPH转运至所有肝微粒体的细胞色素P450氧化酶(Cytochrome P450monooxygenases,CYP)中的唯一供体。药物、类固醇激素等物质的代谢和转化需要CYP参与。POR基因具有遗传多态性,遗传变异可以改变CYP活性,引起P450氧化还原酶缺陷(P450 oxidoreductase deficiency,PORD)、临床药物代谢和反应差异。本文将从POR的结构功能、基因突变引起的疾病及其对酶活性影响三个方面进行论述,总结近年来POR遗传多态性对CYP酶影响的最新研究进展。 Cytochrome P450 oxidoreductase （POR） is the only electron dornor for transferring electrons from NADPH to all microsome Cytochrome P450 monooxygenases（CYP）.CYP is involved in the metabolism and transformation of drugs ,steroids and other substances. Polymorphisms and genetic variations of POR change the activity of CYP, resulting in P450 oxidoreductase deficiency （PORD）, differences on drug metabolism and reaction. The review summarizes the recent research progress on influence of POR genetic polymorphisms on CYP from three parts： structure and function, disease and influence on enzymes.
作者 黄路 阳国平
机构地区 中南大学药学院 中南大学湘雅三医院
出处 《中国临床药理学与治疗学》 CAS CSCD 2013年第7期818-823,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 CYP450氧化还原酶 细胞色素P450氧化酶 P450氧化还原酶缺陷 遗传多态 基因突变 Cytochrome P450 oxidoreduc-tase Cytochrome P450 monooxygenases P450oxidoreduetase deficiency~ Genetic polymor-phism Genetic variation
分类号 R968 [医药卫生—药理学]
  • 相关文献

参考文献37

  • 1胡蕾,高利臣,卓伟,周宏灏,范岚.CYP450氧化还原酶的药物基因组学研究进展[J].中国临床药理学与治疗学,2012,17(7):820-827. 被引量：6
  • 2Gutierrez A,Grunau A,Paine M,et al. Electrontransfer in human cytochrome P450 reductase [J].Biochem Soc Trans, 2003,31(Pt 3) : 497 — 501.
  • 3FluckCE,MullisPE,Pandey AV. Modeling of hu-man P450 oxidoreductase structure by in silico mu-tagenesis and MD simulation[J]. Mol Cell Endocri-nol, 2009,313(1/2): 17 — 22.
  • 4Xia C,Hamdane D, Shen AL,et al. Conformationalchanges of NADPH-cytochrome P450 oxidoreduc-tase are essential for catalysis and cofactor binding[J]. J Biol Chem, 2011, 286(18): 16246-16260.
  • 5Xia C, Panda SP, Marohnic CC, et al. Structuralbasis for human NADPH-cytochrome P450 oxi-doreductase deficiency[J]. Proc Natl Acad Sci USA,2011, 108(33): 13486 — 13491.
  • 6Feidt DM, Klein K, Nussler A, et al. RNA-inter-ference approach to study functions of NADPH :cytochrome P450 oxidoreductase in human hepato-cytes[J]. Chem Biodivers, 2009,6(11): 2084 —2091.
  • 7Polusani SR, Kar R,Riquelme MA,et al. Regula-tion of gap junction function and Connexin 43 ex-pression by cytochrome P450 oxidoreductase (CY-POR) [J]. Biochem Biophys Res Commun, 2011,411(3): 490-495.
  • 8Hall CN,Keynes RG, Garthwaite J. CytochromeP450 oxidoreductase participates in nitric oxide con-sumption by rat brain [J]. Biochem J, 2009,419(2): 411 — 418.
  • 9Huang N, Agrawal V, Giacomini KM, et al. Ge-netics of P450 oxidoreductase : sequence variation in842 individuals of four ethnicities and activities of 15missense mutations [J], Proc Natl Acad Sci USA,2008, 105(5): 1733-1738.
  • 10Agrawal V,Huang N. Miller WL. Pharmacogenet-ics of P450 oxidoreductase: effect of sequence vari-ants on activities of CYP1A2 and CYP2C19 [J].Pharmacogenet Genomics, 2008,18(7) . 569 — 576.

二级参考文献86

  • 1李金恒.临床个体化用药中的药物基因组学考虑[J].中国临床药理学与治疗学,2007,12(4):361-365. 被引量：17
  • 2Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety [ J ]. Drug Metab Dispos, 1998, 26 ( 12 ) : 1217 - 1222.
  • 3Kresge N, Simoni RD, Hill RL. Hemorrhagic sweet clover disease, dicumarol and warfarin: the work of Karl Paul Link[ J ]. J Biol Chem, 2005, 280 : e5 - e6.
  • 4Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin[ J]. J Biol Chem, 1974, 249(19) : 6347 - 6350.
  • 5Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin [J]. Proc Natl Acad Sci USA, 1974, 71(7) :2730 -2733.
  • 6Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 [ J ]. Nature, 2004, 427(6974) :537 -541.
  • 7Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase[J]. Nature, 2004, 427(6974) :541 -544.
  • 8Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors[ J]. Blood, 1998, 92 ( 12 ) :4554 -4559.
  • 9Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes in- volved in its action and metabolism [ J]. Hum Genet, 2007, 121 (1) :23 -34.
  • 10Voora D, Eby C, Linder MW, Milligan PE, Bukaveekas BL, McLeod HL, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype [ J]. Thromb Haemost, 2005, 93 (4) :700 - 705.

共引文献9

同被引文献53

  • 1程婕,杨凌.细胞色素P450氧化还原酶的研究进展[J].中国药理学通报,2006,22(2):129-133. 被引量：26
  • 2戴春岭,李苏,梁永钜,廖海,闫琳,符立梧.建立一种测定细胞色素P450 3A4活性的方法[J].中国药学杂志,2006,41(18):1420-1423. 被引量：5
  • 3姜敏,熊玉卿.细胞色素氧化酶P4503A4与药物代谢[J].实用临床医学（江西）,2006,7(11):199-201. 被引量：10
  • 4Guengerich FP, Wu ZL, Bartleson CJ. Function of human cytochrome P450s: characterization of the orphans[J]. Biochem Biophys Res Commun, 2005, 338(1) :465-469.
  • 5Nelson DR, Nebert DW. Cytoehrome P450 (CYP) gene superfamily[J], eLS, 2011,17(1) :258-261.
  • 6Nebert DW, Russell DW. Clinical importance of the cytochromesP450[J]. Lancet, 2002, 360(9340): 1155-1162.
  • 7Atkins WM. Non-Michaelis-Menten kinetics in cy- tochrome P450-catalyzed reactions[J]. Annu Rev Pharmacol Toxicol, 2005, 45 (2) : 291-310.
  • 8Denisov IG, Frank DJ, Sligar SG, et al. Coopera- tive properties of cytochromes P450[J]. Pharmacol Ther, 2009, 124(2) :151-167.
  • 9Denisov IG, Sligar SG. A novel type of allosteric regulation: Functional cooperativity in monomeric proteins[J]. Arch Biochem Biophys, 2012, 519 (2) :91-102.
  • 10Niwa T, Murayama N, Yamazaki H, et al. Het- erotropic cooperativity in oxidation mediated by cy- tochrome P450[J]. Curt Drug Metab, 2008, 9(5) : 453-462.

引证文献3

二级引证文献8

中国临床药理学与治疗学
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部